Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2009
Date:10/19/2009

ults from the MADIT-CRT trial, which clearly demonstrated that CRT-D therapy slows the progression of heart failure, and we completed enrollment in the PLATINUM workhorse trial evaluating our next-generation PROMUS® Element(TM) Everolimus-Eluting Coronary Stent System. We also obtained key product approvals, including CE Mark for the LATITUDE Patient Management System and FDA approval of the TAXUS® Liberte® Long Paclitaxel-Eluting Coronary Stent System. These developments are further evidence of the strength and promise of our CRM and Cardiovascular businesses."

Guidance for Fourth Quarter and Full Year 2009

The Company estimates net sales for the fourth quarter of 2009 of between $2.025 billion and $2.125 billion. Adjusted earnings -- excluding acquisition-related credits, restructuring and restructuring-related costs, and amortization expense -- are estimated to range between $0.17 and $0.21 per share. The Company estimates net income on a GAAP basis of between $0.20 and $0.25 per share.

The Company has updated its net sales estimate for the full year of 2009 to between $8.134 billion and $8.234 billion. The Company now expects adjusted earnings for the full year -- excluding intangible asset impairment charges; acquisition-, divestiture-, and litigation-related net charges; restructuring and restructuring-related costs; discrete tax items; and amortization expense -- of between $0.75 and $0.79 per share. The Company expects net income on a GAAP basis of between $0.43 and $0.48 per share.

Boston Scientific officials will be discussing these results with analysts on a conference call at 8:00 a.m. (ET) Tuesday, October 20. The Company will webcast the call to all interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one y
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
3. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
6. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress
8. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
9. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
(Date:9/30/2014)... , Sept. 30, 2014 In 2011, approximately ... abused prescription pain relievers (e.g. opioids). 1 ... maintenance treatment, which entails the use of buprenorphine, buprenorphine/naloxone, ... treatments are important when developing and improving care management ... benefit manager Prime Therapeutics LLC (Prime). ...
(Date:9/30/2014)... , Sept. 30, 2014  Life Science Angels ... on supporting promising emerging biotech, medical device, genomics, ... the Top Angel Investment Group in the U.S.  ... best performer out of 370 angel groups analyzed ... network strength (connections), selection aptitude and brand recognition.  ...
Breaking Medicine Technology:Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3
... Thousands of jobs in Ohio supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
... 27, 2011 Codexis, Inc. (Nasdaq: CDXS ... of a joint development agreement to develop an improved ... is Brazil,s largest sugar and ethanol producer.   ... Codexis will deploy the Codexis CodeEvolver™ directed evolution technology ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:9/30/2014)... Pittsburgh School of Dental Medicine have been awarded a ... Dental and Craniofacial Research, part of the National Institutes ... roots of cleft lip and cleft palate and to ... the Philippines and Pennsylvania. , Orofacial clefts (OFCs), ... that can form when a baby,s mouth doesn,t develop ...
(Date:9/30/2014)... that some stickleback fish fathers can have long-term effects ... fish dads cause their offspring to behave in a ... behavioral changes are accompanied by changes in gene expression, ... in the Proceedings of the Royal Society B: ... that moms are very important for their offspring," said ...
(Date:9/30/2014)... RISC Networks Corporation, the leader ... data center, cloud and core network infrastructure. RISC ... of helping more than 5,000 businesses solve complex ... as IT infrastructure transformation, cloud IaaS and data ... engagement rates and partner growth seen in 2014 ...
(Date:9/30/2014)... 30, 2014 Speaking on this occasion, ... observed ‘Nursing Conference’ as a remarkable event, which brings ... medical and clinical research and diagnostic companies, leading universities ... a perfect platform to share experience, foster collaborations across ... world. Nursing Conference is a forum to explore issues ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
Breaking Medicine News(10 mins):Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3
... Dec. 7 Transcept Pharmaceuticals,Inc. today announced that Glenn ... an expert panel on "Drug Development in a,Changed Environment" ... Westin New York Hotel at Times Square on Thursday, ... multi-company panel will be moderated by Ken Trbovich, Vice,President, ...
... Ventures, a health and life,sciences focused venture capital firm ... of the firm., "We are pleased to name ... Partner of Radius. "David has demonstrated an outstanding,ability to ... have his,energy and continued contribution as we develop Radius ...
... one of the commonest surgical procedures performed on ... both physical and psychological harm, while recent evidence ... debate the issue in this weeks BMJ. , ... infant circumcision, yet ritual (non-therapeutic) male circumcision continues ...
... inadequate and should be replaced with charters of health ... But even these raise ethical tensions, says Harald Schmidt, ... Medical Association (BMA) recently called for a charter setting ... Service and what patients can expect from the NHS. ...
... 7 Bond,Laboratories, Inc. (OTC Bulletin Board: BNDB), a ... file with the NASD to implement,a 2-for-1 forward split ... as of the record date will receive,two (2) shares ... For,example, shareholders owning 5,000 shares prior to the stock ...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 7, ... in,the development of microRNA-based diagnostics and therapeutics, announced,today that ... Rosetta Genomics,will present at RBC Capital Markets 2007 Healthcare ... the Westin Hotel in New York., A live ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2Health News:Is infant male circumcision an abuse of the rights of the child? 2Health News:Concept of patients' charters 'inadequate' 2Health News:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: